Peptic-ulcer disease in the elderly

Clinics in Geriatric Medicine

Volumn 15, Issue 3, 1999, Pages 457-471

  Borum, M L ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTACID AGENT; ANTIBIOTIC AGENT; BISMUTH SALICYLATE; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; RANITIDINE BISMUTH CITRATE; SUCRALFATE; TETRACYCLINE;

AGED; AGING; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; PATHOGENESIS; PATHOPHYSIOLOGY; PEPTIC ULCER; PREVALENCE; REVIEW; STOMACH OBSTRUCTION;

EID: 0032814527     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0749-0690(18)30042-9     Document Type: Review

References (93)

1. Aird I. Bewtall H. Mehigan J.A. The blood groups in relation to peptic ulcerations and carcinoma of colon, rectum, breast and bronchus Br Med J 3 1954 315
2. al-Assi M.T. Ramirez F.C. Lew G.M. Clarithromycin, tetracycline, and bismuth: A new non-metronidazole therapy for Helicobacter pylori infection Am J Gastroenterol 89 1994 1203 1205
3. Allen A. Cunliffe W.J. Pearson J.P. The adherent gastric mucus gel barrier in man and changers in peptic ulceration J Intern Med 732 suppl 1990 83 90
4. Allen A. Hutton D. McQueen S. Dimensions of gastroduodenal surface pH gradients exceed those of adherent mucus gel layers Gastroenterology 85 1983 463 466
5. Andersson T. Omeprazole drug interaction studies Clin Pharmacokinet 21 1991 195 212
6. Aymard J.P. Aymard B. Netter P. Haematological adverse effects of histamine H2-receptor antagonists Med Toxicol Adverse Drug Exp 3 1988 430 438
7. Baciewicz A.M. Baciewicz F.A. Jr Effect of cimetidine and ranitidine on cardiovascular drugs Am Heart J 118 1989 144 154
8. Berkowicz J. Lee A. Person-to-person transmission of Campylobacter pylori [letter] Lancet ii 1987 680 681
9. Bianchi Porro G. Parente F. Side effects of anti-ulcer prostaglandins: An overview of the worldwide clinical experience Scand J Gastroenterol 164 Suppl 1989 224 229
10. Borody T.J. Cole P. Noonan S. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication Med J Aust 151 1989 431 435
11. Borsch G. Mai U. Muller K.M. Monotherapy or poly chemotherapy in the treatment of Campylobacter pylori-related gastroduodenal disease Scand J Gastroenterol 23 suppl 142 1988 101 106
12. Chiba N. Rao B.C. Rademaker J.W. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori Am J Gastroenterol 87 12 1992 1716 1727
13. Chiba N. Wilkinson J. Hunt R.H. Omeprazole and clarithromycin in Helicobacter pylori eradication: A meta-analysis Gastroenterology 110 1996 A80
14. Clinch D. Banerjee A.K. Ostick G. Absence of abdominal pain in elderly patients with peptic ulcer Age Aging 13 1984 120 123
15. Coghlan J.G. Gilligan D. Humphries H. Campylobacter pylori and recurrence of duodenal ulcers: A 12 month follow-up study Lancet ii 1987 1101 1109
16. Coleman J.A. Denham M.J. Perforation of peptic ulceration in the elderly Age Aging 9 1980 257 261
17. Collen M.J. Stanczak V.J. Ciarleglio C.A. Refractory duodenal ulcers (nonhealing duodenal ulcers with standard doses of antisecretory medication) Dig Dis Sci 34 1989 233 237
18. Conn H.O. Blitzer B.L. Nonassociation of adrenocorticosteroid therapy and peptic ulcer N Engl J Med 294 1976 473 479
19. Connor B.A. Gastrointestinal disorders of the stomach and duodenum in the elderly Gelb A.M. Clinical Gastroenterology in the Elderly 1996 Marcel Dekker New York 37 72
20. Cooper B.T. Neumann C.S. Upper gastrointestinal endoscopy in patients aged 80 years or more Age Ageing 15 1986 343 349
21. Cooper B.T. Weston C.F. Newmann C.S. Acute gastrointestinal hemorrhage in patients aged 80 years or more Q J Med 68 1988 765 774
22. Cryer B. Lee E. Feldman M. Factors influencing gastroduodenal mucosal prostaglandin concentrations: roles of smoking and aging Ann Intern Med 116 1992 636 640
23. Cryer B. Redfoern J.S. Goldschmiedt M. Effect of aging on gastric and duodenal mucosal prostaglandin concentrations in humans Gastroenterology 102 1992 1118 1123
24. deBoer W. Driessen W. Jansz A. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection Lancet 345 1995 817 820
25. Doll R. Jones F.A. Pygott F. Effect of smoking on the production and maintenance of gastric and duodenal ulcers Lancet i 1958 657
26. Drumm B. Perez-Perez Gl Blaser M.J. Intrafamilial clustering of Helicobacter pylori infection N Engl J Med 322 1990 359 363
27. Elashoff J.D. Grossman M.I. Trends in hospital admissions and death rates for peptic ulcer in the United States from 1970 to 1978 Gastroenterology 78 1980 280 285
28. Freston J.W. Clinical significance of hypergastrinaemia: Relevance to gastrin monitoring during omeprazole therapy Digestion 51 suppl 1 1992 102 114
29. Glupczynski Y. Burette A. Labbe M. Campylobacter pylori associated gastritis: A double-blind placebo-controlled trial with amoxicillin Am J Gastroenterol 83 1988 365 367
30. Glupczynski Y. Delmee M. Burck C. Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents Eur J Epidemiol 4 1988 154 157
31. Goldschmiedt M. Barnett C.C. Schwarz B.E. Effect of age on gastric acid concentrations in healthy men and women Gastroenterology 101 1991 977 990
32. Gorbach S.L. Bismuth therapy in gastrointestinal diseases Gastroenterology 99 1990 863 875
33. Graham D.Y. Lew G.M. Evans D.G. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing: A randomized controlled tria Ann Intern Med 115 1991 266 269
34. Graham D.Y. Malaty J.M. Evans D.G. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States: Effect of age, race, and socioeconomic status Gastroenterology 100 1991 1495 1501
35. Griffin M.R. Piper J.M. Daugherty J.R. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons Ann Intern Med 114 1991 257 262
36. Griffin M.R. Ray W.A. Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons Ann Intern Med 109 1988 359 363
37. Hansten P.D. Drug interactions with antisecretory agents Aliment Pharmacol Ther 5 suppl 1 1991 121 128
38. Haram E.M. Weberg R. Berstad A. Urinary excretion of aluminum after ingestion of sucralfate and an aluminum-containing antacid in man Scand J Gastroenterol 22 1987 615 618
39. Hentschel E. Brandstatter G. Dragosics B. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer N Engl J Med 328 1993 308 312
40. Hirschl A.M. Hentschel E. Schutze K. The efficacy of antimicrobial treatment in Campylobacter pylori associated gastritis and duodenal ulcer Scand J Gastroenterol 23 suppl 142 1988 76 89
41. Hosking S.W. Ling T.K. Yung Y. Randomised controlled trial, of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer Br Med J 305 1992 502 504
42. Howden C.W. Clinical pharmacology of omeprazole Clin Pharmacokinet 20 1991 38 49
43. Isenberg J.I. Hogan D.L. Koss M.A. Human duodenal mucosal bicarbonate secretion. Evidence for basal secretion and stimulation by hydrochloric acid and a synthetic prostaglandin El analogue Gastroenterology 91 1986 370 378
44. Isenberg J.I. McQuaid K.R. Laine L. Acid-peptic disorders Yamada T. Alpers D.H. Owyang C. Textbook of Gastroenterology ed 2. 1995 JB Lippincott Philadelphia 1347 1430
45. Jensen R.T. Collen M.J. Pandol S.J. Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states N Engl J Med 308 1983 883 887
46. Kane E. Fried G. McSherry C.K. Perforated peptic ulcer in the elderly J Am Geriatr Soc 29 1981 224 227
47. Kurata J.H. Ulcer epidemiology: An overview and proposed research framework Gastroenterology 96 2 part 2 suppl 1989 569 580
48. Lambert T. Megraud F. Gerbaud G. Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents Antimicrob Agents Chemother 30 1986 510 511
49. Langtry H.D. Grant S.M. Goa K.L. Famotidine: An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases Drugs 38 1989 551 590
50. Levitt M.D. Review article: Lack of clinical significance of interaction between H2-receptor antagonists and ethanol Aliment Pharmacol Ther 7 1993 131 138
51. Levrat M. Pasquier J. Lambert R. Peptic ulcer in patients over sixty: Experience in 287 cases Am J Dig Dis 11 1966 279 285
52. Lind T. Veldhuyzen van Zanten S. Unge P. Eradication of Helicobacter pylori using one week triple therapies combining omeprazole with two antimicrobials: The MACH 1 study Helicobacter 1 1996 138 144
53. Lindquist M. Edwards I.R. Endocrine adverse effects of omeprazole Br Med J 305 1992 451 452
54. Lipsy R.J. Fennerty B. Fagan T.C. Clinical review of histamine-2 receptor antagonists Arch Intern Med 150 1990 745 751
55. Malaty H.M. Graham D.Y. Klein P.D. Transmission of Helicobacter pylori infection: Studies in families of healthy individuals Scand J Gastroenterol 26 1991 927 932
56. Marshall B.J. Goodwin C.S. Warren J.R. Prospective double blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori Lancet ii 1988 1437 1442
57. Marshall B.J. McGechie D.B. Rogers P.A. Pyloric Campylobacter infection in gastroduodenal disease Med J Aust 142 1985 439 444
58. Martin D.F. Montgomery E. Dobek A.S. Campylobacter pylori, NSAIDs, and smoking: Risk factors for peptic ulcer disease Am J Gastroenterol 84 1989 1268 1272
59. Maxton D.G. Srivastava E.D. Whorwell P.J. Do nonsteroidal anti-inflammatory drugs or smoking predispose to Helicobacter pylori infection? Postgrad Med J 66 1990 717 719
60. McCarthy D.M. Nonsteroidal antiinflammatory drug-induced ulcers: Management by traditional therapies Gastroenterology 96 2 part 2 suppl 1989 662 674
61. McCarthy D.M. Sucralfate N Engl J Med 325 1991 1017 1025
62. McNulty C.A.M. Gearty J.C. Crump B. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth slicylate and erythromycin ethylsuccinate Br Med J Clin Res Ed 293 1986 645 649
63. McNulty C.M. Dent J. Wise R. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents Antimicrob Agents Chemother 28 1985 837 838
64. Messer J. Reitman D. Sacks H.S. Association of adrenocorticosteroid therapy and peptic-ulcer disease N Engl J Med 309 1983 21 24
65. Morgan D. Kraft W. Bender M. Nitrofurans in the treatment of gastritis associated with Campylobacter pylori: The Gastrointestinal Physiology Working Group of Cayetano Heredia and The Johns Hopkins Universities Gastroenterology 95 1988 1178 1184
66. Morris A. Nicholson G. Lloyd C. Seroepidemiology of Campylobacter pyloridis N Z Med J 99 1986 657 659
67. Permutt R.P. Cello J.P. Duodenal ulcer disease in the hospitalized elderly patient Dig Dis Sci 27 1982 1 6
68. Peterson W.L. Ciociola A.A. Sykes D.L. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori, and reducing ulcer recurrence Aliment Pharmacol Ther 10 1996 251 261 and the RBC H. pylori Study Group
69. Peterson W.L. Sturdevant R.A. Frankl H.D. Healing of duodenal ulcer with an antacid regimen N Engl J Med 297 1977 341 345
70. Piper J.M. Ray W.A. Daugherty J.R. Corticosteroid use and peptic ulcer disease of inflammatory bowel disease: Short and long term toxicity Ann Intern Med 114 1991 735 740
71. Price A.B. Levi J. Dolby J.M. Campylobacter pyloridis in peptic ulcer disease: Microbiology, pathology, and scanning electron microscopy Gut 26 1985 1183 1188
72. Rauws E.A. Langenberg W. Houthoff H.J. Campylobacter pyloridis-associated chronic active antral gastritis: A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment Gastroenterology 94 1988 33 40
73. Richter J.M. Colditz G.A. Huse D.M. Cimetidine and adverse reactions: A metaanalysis of randomized clinical trials of short-term therapy Am J Med 87 1989 278 284
74. Robertson J.A. Salusky I.B. Goodman W.G. Sucralfate, intestinal aluminum absorption and aluminum toxicity in a patient on dialysis Ann Intern Med 111 1989 179 181
75. Russell T.L. Berardi R.R. Barnett J.L. Upper gastrointestinal pH in seventy-nine healthy elderly North American men and women Pharmaceut Res 101 1993 87 196
76. Saladin T.A. Geriatric Gastroenterology Sodeman W.A. Jr Saladin T.A. Boyd W.P. Jr The Stomach 1989 WB Saunders Philadelphia 35 48
77. Sax M.J. Clinically important adverse effects and drug interactions with H2-receptor antagonists: An update Pharmacotherapy 7 1987 1100S 1105S
78. Schamburek R.D. Schubert M.L. Control of gastric acid secretion: Histamine H2-receptor antagonists and H-K +-ATPase inhibitors Gastroenterol Clin North Am 21 1992 527 550
79. Seppala K. Farkkila M. Nuutinen J. Triple therapy of Helicobacter pylori infection in peptic ulcer: A 12-month follow-up study of 93 patients Scand J Gastroenterol 27 1992 973 976
80. Sherrard D.J. Aluminum: Much ado about something [editorial] N Engl J Med 324 1991 558 559
81. Shungu D.L. Nalin D.R. Gilman R.H. Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents Antimicrob Agents Chemother 31 1987 949 950
82. Smith S.R. Kendall M.J. Ranitidine versus cimetidine: A comparison of their potential to cause clinically important drug interactions Clin Pharmacokinet 15 1988 44 56
83. Soil A.H. Weinstein W.M. Kurata J. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease Ann Intern Med 114 1991 307 319
84. Solvell L. The clinical safety of omeprazole Digestion 47 suppl l 1990 59 63
85. Sonneberg A. Muller-Lissner S.A. Vogel E. Predictors of duodenal ulcer healing and relapse Gastroenterology 81 1981 1061 1067
86. Steinheber F.U. Ageing and the stomach Clin Gastroenterol 14 1985 657 688
87. Swain C.P. Storey D.W. Bown S.G. Nature of the bleeding vessel in recurrently bleeding gastric ulcers Gastroenterology 90 1986 595 608
88. Tytgat G.N.J. Review article: Treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence Aliment Pharmacol Ther 8 1994 359 368
89. Unge P. Gnarpe H. Pharmacokinetic, bacteriological and clinical aspects on the use of doxycycline in patients with active duodenal ulcer associated with Campylobacter pylori Scand J Infect Dis 53 1988 70 73
90. van Caekenberghe D.L. Breyssens J. In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori) Antimicrob Agents Chemother 31 1987 1429
91. von Wulffen H. Heesemann J. Butzow G.H. Detection of Campylobacter pyloridis in patients with antrum gastritis and peptic ulcers by culture, complement fixation test, and immunoblot J Clin Microbiol 24 1986 716 720
92. Walt R.P. Misoprostol for the treatment of peptic ulcer and antiinflammatory-drug-induced gastroduodenal ulceration N Engl J Med 327 1992 1575 1580
93. Wilson D.E. Antisecretory and mucosal protective actions of misoprostol: Potential role in the treatment of peptic ulcer disease Am J Med 83 1987 2 8